31-oct.-2
013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 m
illion / Net income advances by 42.1 percent to EUR 733 million /
Core ...[+++] earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus
31-okt-2
013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 m
illion / Net income advances by 42.1 percent to EUR 733 million /
Core ...[+++] earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer